Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK+ Non-Small-Cell Lung Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02959619
What this trial is testing

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

Who this might be right for
Solid TumorNon-Small Cell Lung Cancer Metastatic
Betta Pharmaceuticals Co., Ltd. 48
Not applicableStudy completedNCT02718651
What this trial is testing

Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
University of Aarhus 70
Early research (Phase 1)Active Not RecruitingNCT03707938
What this trial is testing

Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Who this might be right for
Advanced Lung CarcinomaALK Gene RearrangementLung Non-Small Cell Carcinoma+4 more
M.D. Anderson Cancer Center 35
Not applicableStudy completedNCT04979988
What this trial is testing

Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients

Who this might be right for
ALK-positive Non-small-cell Lung Cancer
Pfizer 51
Not applicableUnknownNCT04317651
What this trial is testing

Crizotinib in ALK Rearranged Non-small-cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerAdvanced CancerMetastatic Cancer
Fondazione Ricerca Traslazionale 500
Large-scale testing (Phase 3)Study completedNCT01828112
What this trial is testing

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 231
Not applicableEnrolling By InvitationNCT07373951
What this trial is testing

Retrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Status in NSCLC Brain Metastases With External Validation and Survival Analysis

Who this might be right for
Non-Small Cell Lung CancerBrain Metastases
Ming Yang 380
Not applicableNo Longer AvailableNCT02271139
What this trial is testing

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

Who this might be right for
Non-Small Cell Lung Cancer
Genentech, Inc.
Not applicableActive Not RecruitingNCT04881916
What this trial is testing

Immune and Genomic Markers in ALK+ NSCLC

Who this might be right for
Anaplastic Lymphoma Kinase Gene TranslocationNon-Small Cell Lung Cancer
Massachusetts General Hospital 100
Testing effectiveness (Phase 2)Study completedNCT02898116
What this trial is testing

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung CancerCarcinomaNSCLC
Ludwig Institute for Cancer Research 2
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05186506
What this trial is testing

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

Who this might be right for
ALK Fusion Protein ExpressionAdjuvant TherapyNon-Small Cell Lung Cancer
Sichuan University 152
Early research (Phase 1)Study completedNCT01998126
What this trial is testing

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
University of Utah 14
Testing effectiveness (Phase 2)Study completedNCT02314364
What this trial is testing

A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC

Who this might be right for
Non-small Cell Lung Cancer MetastaticTargetable Oncogenes (EGFR, ALK, ROS1)
Massachusetts General Hospital 27
Testing effectiveness (Phase 2)Study completedNCT03256136
What this trial is testing

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

Who this might be right for
Lung Cancer
Massachusetts General Hospital 9
Early research (Phase 1)Looking for participantsNCT07140016
What this trial is testing

Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase (ALK) Positive
Astellas Pharma Global Development, Inc. 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06282536
What this trial is testing

Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial

Who this might be right for
Potentially Resectable ALK Positive Non-Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 20
Early research (Phase 1)Study completedNCT02292550
What this trial is testing

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

Who this might be right for
Non-small Cell Lung Cancer
Novartis Pharmaceuticals 27
Not applicableStudy completedNCT04647110
What this trial is testing

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Who this might be right for
ALK-positive NSCLC
Pfizer 549
Large-scale testing (Phase 3)Active Not RecruitingNCT03052608
What this trial is testing

Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 296
Not applicableUnknownNCT02041468
What this trial is testing

Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

Who this might be right for
Non-small Cell Lung Cancer Metastatic
Jewish General Hospital 29
Next Page